agenda 2024 10 23 24 508

Final Agenda October 23-24, 2024
8:00 Welcome & Introductions Dr. Keipp Talbot (ACIP Chair)
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:20 Pneumococcal Vaccines
Introduction Dr. Jamie Loehr (ACIP, WG Chair)
Economic Analysis and public health impact of PCV use for adults aged
≥50 yearsDr. Charles Stoecker (Tulane University)
Summary of economic analyses of PCV use in adults aged ≥50 years Dr. Andrew Leidner (CDC/NCIRD)
Summary of WG Interpretation of EtR and policy options on PCV use in
adults aged ≥50 yearsDr. Miwako Kobayashi (CDC/NCIRD)
Clinical considerations for PCV use in adults Dr. Miwako Kobayashi (CDC/NCIRD)
10:30 Break
10:40 Influenza Vaccines
Introduction Dr. Jamie Loehr (ACIP, WG Chair)
Vaccine Effectiveness Update       Dr. Sascha Ellington (CDC/NCIRD)
Influenza A/H5 update Dr. Tom Shimabukuro (CDC/NCIRD)
Influenza Vaccines VFC Resolution Dr. Jeanne Santoli (CDC/NCIRD)
11:25 Chikungunya Vaccines
Introduction Dr. Edwin Asturias (ACIP, WG Chair)
Update on chikungunya and chikungunya vaccines Dr. Susan Hills (CDC/NCEZID)
Virus-like particle chikungunya vaccine Dr. Victoria Jenkins (Bavarian Nordic)
Work group interpretation of vaccine data Dr. Susan Hills (CDC/NCEZID)
12:10 Break
12:40 COVID-19 Vaccines
Introduction Dr. Robert Schechter (ACIP, WG Chair)
COVID-19 vaccine uptake and implementation Dr. Georgina Peacock (CDC/NCIRD)
COVID-19 epidemiology Dr. Christopher Taylor (CDC/NCIRD)
COVID-19 vaccine effectiveness Dr. Ruth Link-Gelles (CDC/NCIRD)
Economic analysis of an additional dose of the 2024-2025 COVID-19
vaccineDr. Lisa Prosser (University of Michigan)
EtR Ms. Lauren Roper (CDC/NCIRD)
Clinical considerations Dr. Lakshmi Panagiotakopoulos (CDC/NCIRD)
3:35 Break
3:45 Public Comment
4:05 VOTES
Pneumococcal Vaccines Dr. Miwako Kobayashi (CDC/NCIRD)
Influenza Vaccines VFC Dr. Jeanne Santoli (CDC/NCIRD)
COVID-19 Vaccines Ms. Lauren Roper (CDC/NCIRD)
4:35 Respiratory Syncytial Virus (RSV) Vaccines - Maternal/Pediatric
Introduction Dr. Helen Chu (ACIP,WG Chair)
Safety and efficacy of clesrovimab Dr. Anushua Sinha (Merck)
Maternal RSV vaccine safety Dr. Malini B. DeSilva (Health Partners Institute)
Workgroup considerations Ms. Danielle Moulia (CDC/NCIRD)
5:30 RecessMEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)
Centers for Disease Control and Prevention
Atlanta, Georgia 30329
October 23-24, 2024
Wednesday, October 23, 2024
Final Agenda October 23-24, 2024
8:00 Welcome & Introductions Dr. Keipp Talbot (ACIP Chair)
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:10 Agency Updates CDC, CMS, FDA, HRSA, IHS, OIDP, NIH)
8:30 Meningococcal Vaccines
Introduction Dr. Jamie Loehr (ACIP, WG Chair)
Economic analysis of GSK MenABCWY vaccine and comparison of
GSK and CDC analysesDr. Xiaoyu Dong (CDC/NCIRD)
GRADE/EtR for GSK MenABCWY vaccine Dr. Sarah Schillie (CDC/NCIRD)
Introduction to Bexsero interval and dosing label change Dr. Sarah Schillie (CDC/NCIRD)
EtR for Bexsero interval and dosing change Dr. Sarah Schillie (CDC/NCIRD)
Summary of work group considerations regarding Bexsero interval and
dosing changeDr. Sarah Schillie (CDC/NCIRD)
10:30 Break
10:45 Respiratory Syncytial Virus (RSV) Vaccines - Adult
Introduction Dr. Albert Shaw (ACIP, WG Chair)
Moderna coadministration with high-dose influenza vaccine TBD (Moderna)
Pfizer immunogenicity in immunocompromised adults, coadministration
with COVID-19 and high-dose influenza vaccinesDr. Iona Munjal (Pfizer)
GSK season 3 efficacy, immunogenicity in immunocompromised adults Dr. Susan Gerber (GSK)
FDA self-controlled case series GBS update Dr. Patricia Lloyd (FDA)
Work Group interpretations Dr. Michael Melgar (CDC/NCIRD)
12:45 Break
1:15 Immunization Schedules
Introduction to 2025 adult and child/adolescent immunization schedule Dr. Sybil Cineas (ACIP, WG Chair)
2025 child and adolescent schedule revisions             Dr. Nanda Issa (CDC/NCIRD)
2025 adult schedule revisions Dr. Patricia Wodi (CDC/NCIRD)
2:15 Break
2:25 Public Comment
2:45 VOTES
Meningococcal Vaccines Dr. Sarah Schillie (CDC/NCIRD)
Meningococcal VFC Dr. Jeannie Santoli (CDC/NCIRD)
Immunization Schedules Dr. Patricia Wodi (CDC/NCIRD)
3:05 Break
3:15 Human papillomavirus (HPV) Vaccines
Introduction Dr. Oliver Brooks (ACIP, WG Chair)
Introduction to policy consideration: reduced number of doses Dr. Lauri Markowitz (CDC/NCIRD)
Introduction to policy consideration: wording of the age for routine
vaccination Dr. Ruth Stefanos (CDC/NCIRD)
Review of the literature on HPV vaccination at ages 9-10 to increase
coverageDr. Sarah Brewer (CDC/NCIRD)
Work group - next steps Dr. Carla DeSisto (CDC/NCIRD)
4:30 Cytomegalovirus (CMV) Vaccine
Introduction: formation of the CMV vaccine workgroup Dr. Denise Jamieson (ACIP, WG Chair)
4:40 Mpox Vaccine
Clade 1 Mpox Outbreak in Africa:   Situational Update Dr. Agam Rao (CDC/NCEZID)
5:00 AdjournThursday, October 24, 2024
Final Agenda October 23-24, 2024
Acronyms
CDC Centers for Disease Control and Prevention
CMS Centers for Medicare and Medicaid Services
CORVD Coronavirus and Other Respiratory Viruses Division
COVID-19 Coronavirus disease 2019
EtR Evidence to Recommendations Framework
FDA Food and Drug Administration
GRADE
HRSA Health Resources and Services Administration
HPV Human papillomavirus
IHS Indian Health Service
ISO Immunization Safety Office
NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention
NCIRD National Center for Immunization & Respiratory Diseases
NCEZID National Center for Emerging and Zoonotic Diseases
NIAID National Institute of Allergy and Infectious Diseases
OIDP Office of Infectious Disease and HIV/AIDS Policy
RSV Respiratory Syncytial Virus (RSV)
SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2
WG Work Group
WHO World Health Organization
VAERS Vaccine Adverse Event Reporting System
VE Vaccine Effectiveness
VFC Vaccines for ChildrenGrading of Recommendations Assessment, Development and Evaluation

Summary: Final Agenda October 23-24, 2024 8:00 Welcome & Introductions Dr. Keipp Talbot (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC) 8:20 Pneumococcal Vaccines  Introduction Dr. Jamie Loehr (ACIP, WG Chair) Economic Analysis and public health impact of PCV use for adults aged  ≥50 yearsDr. Charles Stoecker (Tulane University) Summary of economic analyses of PCV use in adults aged ≥50 years Dr. Andrew Leidner (CDC/NCIRD) Summary of WG Interpretation of EtR and policy options on PCV…